The natural history of lower urinary tract symptoms over five years

European Urology

Volumn 43, Issue 4, 2003, Pages 374-380

  Temml, Christian ^a   Brössner, Clemens ^b   Schatzl, Georg ^c   Ponholzer, Anton ^d,e   Knoepp, Leise ^f   Madersbacher, Stephan ^d,e  

^a Department of Preventive Health ^*  (Austria)

^b Krankenhaus Oberwart   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d DANUBE HOSPITAL   (Austria)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^f LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; Medical therapy; Progression; Risk factor

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL EXAMINATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; QUESTIONNAIRE; RISK FACTOR; SYMPTOM; URETHRA;

EID: 0037389875     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00084-8     Document Type: Article

References (23)

1. Meigs JB, Barry MJ. Natural history of benign prostatic hyperplasia. In: Kirby R, McConnell J, Fitzpatrick J, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media Ltd.; 1996. p. 125-35.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
3. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428-36.
4. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001;58(6A):5-16.
5. Roehrborn CG, Bartsch G, Kirby R, Andriole G, Boyle P, de la Rosette J, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001;58:642-50.
6. Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of 5 years. Eur Urol 1998;34:325-32.
7. Madersbacher S, Haidinger G, Temml C, Schmidbauer CP for the Prostate Study Group of the Austrian Society of Urology. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol 1998;34:136-41.
8. Haidinger G, Madersbacher S, Waldhoer T, Lunglmayr G, Vutuc C. The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. Eur J Epidemiol 1999;15:717-22.
9. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001;39:390-9.
10. Barry MJ, Fowler FL, Bin L, Pitts III C, Harris CJ, Mulley Jr AG. The natural history of patients with benign prostatic hyperplasia as diagnosed by north American urologists. J Urol 1997;157:10-5.
11. Girman CJ, Panser LA, Chute CG, Oesterling JE, Barrett DM, Chen CC, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol 1993;150:887-92.
12. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
13. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted county study of urinary symptoms and health status. J Urol 1999;162:1301-6.
14. Sarma AV, Jacobsen SJ, Girman CJ, Jacobsen DJ, Roberts RO, Rhodes T, et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002;168:1446-52.
15. Madersbacher S, Haidinger G, Struhal G for the Prostate Study Group of the Austrian Society of Urology. Management of lower urinary tract symptoms of elderly men in Austria. Eur Urol 2001;39:145-50.
16. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998;160:12-6.
17. Roberts RO, Jacobsen SJ, Rhodes T, Guess HA, Girman CJ, Panser LA, et al. Cigarette smoking and prostatism: a biphasic association? Urology 1994;43:797-801.
18. Planz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol 1999;149:106-15.
19. Sidney S, Quensberry C, Sadler MC, Lydick EG, Guess HA, Cattolica EV. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 1991;38(Suppl):13-9.
20. Koskimäki J, Hakama M, Huhtala H, Tammela TLJ. Association of non-urological diseases with lower urinary tract symptoms. Scand J Urol Nephrol 2001;35:377-81.
21. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999;162:376-82.
22. Roehborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53:473-80.
23. Roehrbor CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. The PLESS Study Group. Urology 1999;54:662-9.